Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades UroGen Pharma to Hold, Lowers Price Target to $10

Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.
byBenzinga Newsdesk
February 8, 2023
1 minute read
Total
0
Shares
0
0
0
0
0
0

Jefferies analyst Chris Howerton downgrades UroGen Pharma (NASDAQ:URGN) from Buy to Hold and lowers the price target from $35 to $10.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts